Call for Abstracts

Abstract Submission

Important Deadlines

Call for Abstracts Submission Opens July 1st 2023 July 1st 2023
Abstract Submission Deadline 23:59 JST on October 16th 2023
Notification of Acceptance/Rejection December 8th 2023

Submission Guidelines

  • Abstracts will be accepted in English only
  • All abstracts must not exceed 500 words
  • A table or figure will count as 150 words
  • The total word count does not include the title, authors’ details or references
  • The name of the presenting author must appear first in the list of authors
  • An international panel of reviews will review all abstracts anonymously
  • There is no fee for submitting an abstract
  • There is no limit to the number of poster abstracts you may submit
  • CINP recommends using the NbN nomenclature for psychotropics (

Abstract submissions must be structured with the following:

  • Background
  • Aims & Objectives
  • Method
  • Results
  • Discussion & Conclusion
  • References – Use Harvard style, where each reference is numbered in order of use
  • Keywords – Mandatory to include three

Presentation Types

  • Oral Presentation: A limited number of abstracts will be selected as 15-min oral presentations (12 minutes presentation plus 3 minutes of Q&A) in one of the Oral Abstract sessions. If you are not comfortable providing an oral presentation, please only select poster presentation during submission.
  • Poster Presentation: Abstracts not selected for oral presentation will be provided a poster presentation. Top rated posters will be selected as 5-minute presentations (3 minutes presentation plus 2 minutes Q&A) in one of the Data Blitz sessions.

Submission Topics

The CINP International Scientific Programme Committee welcomes abstracts that link the latest, and ground-breaking, preclinical developments with the clinical research on a given topic. Through the free and open exchange of ideas, CINP supports a strong focus on new approaches to the development and assessment of CNS pharmaceuticals by researchers working in both academia and industry.

Please find below the list of topics:

Topic 1: Research Topic 2: By Disorder Topic 3: By Drug Methodology
• Clinical • Addiction Disorders • Animal Models
• Preclinical • Anxiety Disorders • Anxiolytics
• Translational • Attention Deficit Disorders • Brain Stimulation
• Others • Autism • Computational Neuroscience
• Bipolar Disorders • Drugs for Bipolar Disorders
• Childhood & Adolescent Disorders • Drugs for Depression
• COVID-19 • Drugs for Insomnia
• Dementia • Drugs for Psychosis
• Depression • Ethics of Psychopharmacology
• Eating Disorders • Genetics
• Epilepsy • History of Psychopharmacology
• Obsessive-Compulsive Disorders • Imaging
• Pain • Molecular Neurobiology/Pharmacology
• Panic Disorders • Neuropathology/Post-Mortem Studies
• Personality Disorders • Neurophysiology
• Post-Traumatic Stress Disorders • Oriental Medicine
• Premenstrual Dysphoric Disorder • Pharmacoeconomics
• Schizophrenia • Pharmacogenetics/Kinetics
• Sexual Disorders • Psychoneuroimmunology
• Sleep Disorders • Transcultural Psychopharmacology
• Suicide • Others
• Others
Abstract Submission

© 2024 CINP World Congress of Neuropsychopharmacology. All Rights Reserved